| M | T | W | T | F | S | S | |
|---|---|---|---|---|---|---|---|
 | 1 | 2 | 3 | 4 | 5 | 6 | 7 |
| 8 | 9 | 10 | 11 | 12 | 13 | 14 |
| 15 | 16 | 17 | 18 | 19 | 20 | 21 |
| 22 | 23 | 24 | 25 | 26 | 27 | 28 |
| 29 | 30 | 31 |
NEUREN PHARMACEUTICALS LIMITED (NEU)
Stock Code: NEU
Listing Date: 2005-02-03 00:00:00
Website: http://www.neurenpharma.com/
Industry: Pharmaceuticals, Biotechnology & Life Sciences
Principal Activities:
Biopharmaceutical company with a focus on neuroprotection and metabolism.
Address:
122 Arthur Street, C/o Barnes Dowell James
NORTH SYDNEY
NSW 2060
Phone: +64 9 529 3942
Fax: +64 9 529 3941
Executives & Directors
Dr Robin Congreve, Chairman
Dr Parmjot Bains, CEO
Mr Larry Glass, CEO
Mr Tom Amos, Non Exec. Director
Mr Trevor Scott, Non Exec. Director
Dr Douglas Wilson, Non Exec. Director
Dr Graeme Howie, Non Exec. Director
Mr Rob Turnbull, CFO
Mr Robert Waring, Company Secretary
Company Podcasts
Subscribe to current and future audio events for this company by clicking on the podcast icon:
Company ASX Announcements
Company ASX announcements can be viewed on the ASX website.
Announcements from the preceding six months are shown below.
Click here to view this company's details on the ASX site
Company Events
NEU - Further Validation of NNZ-2566 as a Traumatic Brain Injury Treatment - Mr David Clarke, CEO
|
Wed, 14 Feb 2007 01:30PM |
|
| Interim Results | Fri, 29 Aug 2008 | |
| Annual General Meeting | Thu, 29 May 2008 12:30PM |
|
| Full Year Results | Fri, 29 Feb 2008 | |
| EGM | Fri, 12 Oct 2007 12:30PM |
|
| Interim Results | Fri, 31 Aug 2007 | |
| Annual General Meeting | Wed, 23 May 2007 12:30AM |
|
| Full Year Results | Fri, 16 Mar 2007 | |
| Interim Results | Tue, 12 Sep 2006 | |
| Annual General Meeting | Wed, 3 May 2006 12:00AM |
|
| Full Year Results | Tue, 28 Feb 2006 | |
| Annual General Meeting | Mon, 30 May 2005 12:30PM |
NEUREN PHARMACEUTICALS LIMITED (NEU)
| Foreign Shareholder Notice re Rights Issue | Wed, 19 Dec 2007 |
| Optionholder Notice re Rights Issue | Wed, 19 Dec 2007 |
| Shareholder Notice re Rights Issue | Wed, 19 Dec 2007 |
| Section 708AA Notice | Wed, 19 Dec 2007 |
| Appendix 3B - Non-renounceable Rights Issue | Wed, 19 Dec 2007 |
| Rights Issue NZ Investment Statement and Prospectus | Wed, 19 Dec 2007 |
| D Clarke Appendix 3Z | Wed, 19 Dec 2007 |
| Neuren announces non-renounceable rights issue | Wed, 19 Dec 2007 |
| Rights Issue Letter of Offer | Wed, 19 Dec 2007 |
| Trading Halt | Mon, 17 Dec 2007 |
| Neuren Clinical Development Update | Tue, 4 Dec 2007 |
| Neuren Corporate Update December 2007 | Mon, 3 Dec 2007 |
| Neuren announces reorganisation | Mon, 12 Nov 2007 |
| NNZ-2566 successful Phase 1b trial results | Wed, 7 Nov 2007 |
| Appendix 4C - quarterly | Wed, 31 Oct 2007 |
| Appendix 3B - issue of convertible notes | Tue, 16 Oct 2007 |
| Appendix 3B - issue of shares | Tue, 16 Oct 2007 |
| Notice under section 708A(5)(e) of the Corporations Act | Tue, 16 Oct 2007 |
| Neuren completes acquisition of Hamilton Pharmaceuticals | Tue, 16 Oct 2007 |
| MBP: Neural Regeneration Peptides (NRP) update - new animal | Mon, 15 Oct 2007 |
| Results of Meeting | Fri, 12 Oct 2007 |
| Notice of Special Meeting of Shareholders | Thu, 27 Sep 2007 |
| Neuren launches Australian Phase 3 Trial Sites | Wed, 26 Sep 2007 |
| Neuren completes moderate TBI safety trial | Thu, 20 Sep 2007 |
| Change in substantial holding | Tue, 11 Sep 2007 |
| NZ arm of Phase 3 trial commences | Fri, 7 Sep 2007 |
| Half Yearly Report and Accounts | Fri, 31 Aug 2007 |
| Corporate Update Presentation | Thu, 23 Aug 2007 |
| Commitments test entity - second quarter | Tue, 31 Jul 2007 |
| Acquisition of Motiva through Hamilton Pharmaceuticals | Tue, 31 Jul 2007 |
| Lapse of Unquoted Options | Tue, 24 Jul 2007 |
Please note: This company appears on this website as a result of its listing on the Australian Securities Exchange. Boardroom Radio does not claim any association with any company listed on this site.